Health ❯ Healthcare ❯ Biotechnology

Therapeutics

Muscle Diseases Regulatory Affairs ENCELTO RNAi-based Therapies Oligonucleotide Therapeutics Patient Outcomes Cancer Treatment Immunological Disorders

Genentech Licenses SanegeneBio RNAi Program in Deal Worth Up to $1.7 Billion

Genentech assumes late-stage development responsibilities following SanegeneBio's early work.

FDA Grants Orphan Drug Status to Cellenkos’ CK0804 for Myelofibrosis

FDA Approves First Eye Implant to Preserve Vision in Rare Macular Telangiectasia